Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00027183
Status:
COMPLETED
Last Update Posted:
2022-06-06
First Post:
2001-11-27
Brief Title:
Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Role of Exotoxins in the Pathogenesis of Pseudomonas Aeruginosa
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Some bacteria that cause disease can produce toxic substances that may worsen the disease Pseudomonas aeruginosa is a bacteria that can produce a variety of toxins and is of special interest for patients with cystic fibrosis and repeated long term lung infections
The goal of this study is to determine whether specific toxins produced by Pseudomonas aeruginosa may be important in the disease process of chronic lung infections of patients with cystic fibrosis
This study will attempt to measure bacterial production of toxins in blood and sputum and immune system response to toxins in the blood
The goal of this study is to determine whether specific toxins produced by Pseudomonas aeruginosa may be important in the disease process of chronic lung infections of patients with cystic fibrosis
This study will attempt to measure bacterial production of toxins in blood and sputum and immune system response to toxins in the blood
Detailed Description:
The goal of this study is to determine whether virulence determinants that use the type III-secretory pathway may be important in the pathogenesis of chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis CF The studies will quantify bacterial effector proteins in serum and sputum and the immune response to specific products as reflected by antibodies in serum Candidate effector proteins include 1 exotoxin A a non-type III-dependent ADP-ribosyltransferase and cytotoxin that does not use the Type III secretory pathway 2 ExoS a type III pathway-dependent extracellular ADP-ribosyltransferase with cytotoxic activity 3 ExoU another type III-dependent cytotoxin that is responsible for epithelial injury in acute lung infections and 4 PcrV a homolog to the V antigen of Yersinia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 98-H-0062 | None | None | None |